# Duquesne Capital Management

> Duquesne Capital Management is a VC fund backing Biotechnology and Pharmaceutical. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 7
- Last investment: Jan 2024
- Lead investor: 29%
- Last updated: Aug 2026

Duquesne Capital Management is a VC fund focused on Biotechnology and Pharmaceutical. Duquesne Capital Management provides its services to high net worth individuals and institutions.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 43% |
| Pharmaceutical | 3 | 43% |
| Energy | 1 | 14% |
| Mobile | 1 | 14% |
| Medical | 1 | 14% |

13 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 29% |
| Series D | 2 | 29% |
| Series A | 1 | 14% |
| Series B | 1 | 14% |
| Funding Round | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Ratio Therapeutics | Ratio Therapeutics develops radiotherapeutics for the treatment of cancers. They engaged in research and development platforms, trillium and macropa, enable the imaging, discovery, and advancement of radiopharmaceuticals. It enables doctors to detect a wide range of epithelial-derived cancers, such as breast, pancreatic, lung, colon cancers, andmore. | $50M | Series B | Jan 17, 2024 |  |
| Ratio Therapeutics | Ratio Therapeutics develops radiotherapeutics for the treatment of cancers. They engaged in research and development platforms, trillium and macropa, enable the imaging, discovery, and advancement of radiopharmaceuticals. It enables doctors to detect a wide range of epithelial-derived cancers, such as breast, pancreatic, lung, colon cancers, andmore. | $20M | Series A | Feb 01, 2023 |  |
| Agensys | Agensys a biotechnology company, engages in the research and development of therapeutic human monoclonal antibodies and antibody drug conjugates for the treatment of cancer. It offers products to treat various tumors, as well as prostate, pancreatic, and bladder cancers. The company, formerly known as UroGenesys, was founded in 1997 and is based inSanta Monica, California. As of December 18, 2007, Agensys, Inc. operates as a subsidiary of Astellas Pharma US, Inc. | $41.3M | Series D | Jul 12, 2007 |  |
| Dilithium Networks | Dilithium® offers high-quality multimedia delivery over mobile and broadband networks to any device. Dilithium provides the most comprehensive and innovative mobile video solutions, with unmatched breadth of deployments in 60 countries reaching over 1 billion subscribers.Dilithium pioneered mobile video communications and our solutions aredeployed by leading network operators, content owners, and aggregators across 2G, 3G, and WiFi networks. | $33M | Series D | Jul 03, 2007 |  |
| BPL Global | BPL Global provides electric utilities with a suite of smart grid solutions that support advanced distribution automation from substations through customer premises. Our solutions collaborate across the grid, helping utilities increase efficiency and reliability to improve their financial, operational and environmental performance. BPLG combinesour experience in applying smart grid solutions with our market-leading technology to successfully serve leading utilities. | $26M | Series C | Feb 15, 2007 |  |
| Kyntra Bio | FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs. The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissuegrowth factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.FibroGen's product Roxadustat is an oral small-molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the China Food and Drug Administration). | $100M |  | Feb 17, 2005 |  |
| Synta Pharmaceuticals | Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. It has a global partnership with Roche for developing novel CRACM inhibitors, an oralcalcium released activated calcium modulator ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. The company also retains rights in various indications and markets to its other drug candidates and programs, which include STA-9090, an Hsp90 inhibitor that is in Phase 1 development; elesclomol, an oxidative stress inducer for the treatment of cancer; and apilimod, an oral IL-12/23 inhibitor, which is in Phase 2 for rheumatoid arthritis. In addition, Synta Pharmaceuticals Corp. is developing STA-9584, a vascular disrupting agent that is in preclinical development. The company was incorporated in 2000 and is based in Lexington, Massachusetts. | $50M | Series C | Jan 14, 2004 |  |

7 of 7 investments shown.

## Co-investors
- [Galleon Group](https://shizune.co/investors/profile/galleon-group) — VC Fund, 2 deals together
- [Schusterman Family Investments](https://shizune.co/investors/profile/schusterman-family-investments) — VC Fund, 2 deals together
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together
- [AL-DEERA Holding](https://shizune.co/investors/profile/al-deera-holding) — VC Fund, 1 deal together
- [Alta Partners](https://shizune.co/investors/profile/alta-partners) — VC Fund, 1 deal together
- [Apothecary Capital](https://shizune.co/investors/profile/apothecary-capital) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Duquesne Capital Management invest in?

Duquesne Capital Management invests primarily in Biotechnology, Pharmaceutical and Energy startups, most often at Series C and Series D stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Duquesne Capital Management last invest?

The most recent investment recorded for Duquesne Capital Management closed in Jan 2024. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co